Indaptus Therapeutics Stock Analysis
| INDP Stock | USD 1.80 0.25 16.13% |
IPO Date 4th of August 2015 | 200 Day MA 6.1871 | 50 Day MA 2.4513 | Beta 1 |
Indaptus Therapeutics holds a debt-to-equity ratio of 0.004. At this time, Indaptus Therapeutics' Debt To Equity is relatively stable compared to the past year. As of 02/08/2026, Debt Equity Ratio is likely to grow to 0.02, while Short and Long Term Debt Total is likely to drop slightly above 72 K. Indaptus Therapeutics' financial risk is the risk to Indaptus Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Indaptus Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Indaptus Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Indaptus Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Indaptus Therapeutics' stakeholders.
For many companies, including Indaptus Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Indaptus Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Indaptus Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 0.9153 | Book Value 2.805 | Enterprise Value | Enterprise Value Ebitda 1.0264 | Shares Float 940.4 K |
Indaptus Therapeutics is undervalued with Real Value of 3.83 and Target Price of 10.0. The main objective of Indaptus Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Indaptus Therapeutics is worth, separate from its market price. There are two main types of Indaptus Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Indaptus Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Indaptus Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Indaptus Stock trading window is adjusted to America/New York timezone.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Indaptus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. Indaptus Stock Analysis Notes
About 36.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.92. Some equities with similar Price to Book (P/B) outperform the market in the long run. Indaptus Therapeutics recorded a loss per share of 29.03. The entity last dividend was issued on the 30th of October 2020. The firm had 1:28 split on the 27th of June 2025. Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York. Indaptus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To learn more about Indaptus Therapeutics call Jeffrey JD at 646 427 2727 or check out https://indaptusrx.com.Indaptus Therapeutics Investment Alerts
| Indaptus Therapeutics generated a negative expected return over the last 90 days | |
| Indaptus Therapeutics has high historical volatility and very poor performance | |
| Indaptus Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (15.02 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Indaptus Therapeutics currently holds about 33.01 M in cash with (12.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.0, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Indaptus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 36.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Acquisition by Ben-tzvi Avraham of 25000 shares of Indaptus Therapeutics subject to Rule 16b-3 |
Indaptus Largest EPS Surprises
Earnings surprises can significantly impact Indaptus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-13 | 2023-12-31 | -0.54 | -0.48 | 0.06 | 11 | ||
2024-08-12 | 2024-06-30 | -0.54 | -0.47 | 0.07 | 12 | ||
2023-11-06 | 2023-09-30 | -0.55 | -0.47 | 0.08 | 14 |
Indaptus Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Vivaldi Capital Management, Llc | 2025-06-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 0.0 | Vanguard Group Inc | 2025-06-30 | 0.0 | Geode Capital Management, Llc | 2025-06-30 | 0.0 | Jpmorgan Chase & Co | 2025-06-30 | 0.0 | Virtu Financial Llc | 2025-06-30 | 0.0 | Investment House Llc | 2025-06-30 | 0.0 | Strategy Asset Managers Llc | 2025-06-30 | 0.0 | Two Sigma Securities, Llc | 2025-03-31 | 0.0 | Sbi Securities Co Ltd | 2025-06-30 | 156 | Tower Research Capital Llc | 2025-06-30 | 108 |
Indaptus Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.04 M.Indaptus Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.35) | (2.24) | |
| Return On Capital Employed | (3.51) | (3.33) | |
| Return On Assets | (2.35) | (2.24) | |
| Return On Equity | (3.43) | (3.26) |
Management Efficiency
Indaptus Therapeutics has return on total asset (ROA) of (1.3138) % which means that it has lost $1.3138 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.1798) %, meaning that it created substantial loss on money invested by shareholders. Indaptus Therapeutics' management efficiency ratios could be used to measure how well Indaptus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/08/2026, Return On Tangible Assets is likely to grow to -2.24. In addition to that, Return On Capital Employed is likely to grow to -3.33. As of 02/08/2026, Total Current Liabilities is likely to drop to about 3.4 M. In addition to that, Liabilities And Stockholders Equity is likely to drop to about 8 M| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.38 | 0.36 | |
| Tangible Book Value Per Share | 0.38 | 0.36 | |
| Enterprise Value Over EBITDA | (12.59) | (13.22) | |
| Price Book Value Ratio | 64.31 | 61.10 | |
| Enterprise Value Multiple | (12.59) | (13.22) | |
| Price Fair Value | 64.31 | 61.10 | |
| Enterprise Value | 247.1 M | 234.8 M |
Management at Indaptus Therapeutics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Technical Drivers
As of the 8th of February, Indaptus Therapeutics retains the Market Risk Adjusted Performance of (0.12), standard deviation of 8.79, and Risk Adjusted Performance of (0.03). Indaptus Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Indaptus Therapeutics Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Indaptus Therapeutics price series with the more recent values given greater weights.
Indaptus Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Indaptus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Indaptus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Indaptus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Indaptus Therapeutics Outstanding Bonds
Indaptus Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Indaptus Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Indaptus bonds can be classified according to their maturity, which is the date when Indaptus Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Indaptus Therapeutics Predictive Daily Indicators
Indaptus Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Indaptus Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Indaptus Therapeutics Forecast Models
Indaptus Therapeutics' time-series forecasting models are one of many Indaptus Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Indaptus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Indaptus Therapeutics Bond Ratings
Indaptus Therapeutics financial ratings play a critical role in determining how much Indaptus Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Indaptus Therapeutics' borrowing costs.| Piotroski F Score | 3 | Frail | View |
| Beneish M Score | (7.01) | Unlikely Manipulator | View |
Indaptus Therapeutics Debt to Cash Allocation
Indaptus Therapeutics currently holds 84.16 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Indaptus Therapeutics has a current ratio of 9.0, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Indaptus Therapeutics' use of debt, we should always consider it together with its cash and equity.Indaptus Therapeutics Total Assets Over Time
Indaptus Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Indaptus Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Indaptus Therapeutics Debt Ratio | 1.25 |
Indaptus Therapeutics Corporate Bonds Issued
Indaptus Short Long Term Debt Total
Short Long Term Debt Total |
|
About Indaptus Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Indaptus Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Indaptus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Indaptus Therapeutics. By using and applying Indaptus Stock analysis, traders can create a robust methodology for identifying Indaptus entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current Indaptus Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Indaptus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Indaptus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 10.0 | Buy | 1 | Odds |
Most Indaptus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Indaptus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Indaptus Therapeutics, talking to its executives and customers, or listening to Indaptus conference calls.
Indaptus Stock Analysis Indicators
Indaptus Therapeutics stock analysis indicators help investors evaluate how Indaptus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Indaptus Therapeutics shares will generate the highest return on investment. By understating and applying Indaptus Therapeutics stock analysis, traders can identify Indaptus Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 13.4 M | |
| Common Stock Shares Outstanding | 9.4 M | |
| Total Stockholder Equity | 3.9 M | |
| Property Plant And Equipment Net | 82.2 K | |
| Cash And Short Term Investments | 5.8 M | |
| Cash | 5.8 M | |
| Accounts Payable | 870.2 K | |
| Net Debt | -5.7 M | |
| 50 Day M A | 2.4513 | |
| Total Current Liabilities | 3.4 M | |
| Other Operating Expenses | 15.4 M | |
| Non Current Assets Total | 720.4 K | |
| Non Currrent Assets Other | 638.3 K | |
| Stock Based Compensation | 2.3 M |
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.